About
Ophthalmology Products
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (14)
View allTotal Trials
14
As Lead Sponsor
14
As Collaborator
0
Total Enrollment
879
By Phase
PHASE3: 4PHASE2: 3PHASE1: 4
By Status
COMPLETED: 7RECRUITING: 2ACTIVE_NOT_RECRUITING: 2TERMINATED: 1APPROVED_FOR_MARKETING: 1AVAILABLE: 1
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07009262Lead Sponsor
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
N/ARecruiting
50 participants
Started: Apr 21, 2025 · Completed: Apr 7, 2026
NCT06467084Lead Sponsor
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
PHASE3Recruiting
48 participants
Started: Jun 24, 2024 · Completed: Aug 31, 2027
NCT05505916Lead Sponsor
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
PHASE3Active, not recruiting
145 participants
Started: Oct 24, 2022 · Completed: Jun 30, 2026
NCT05511922Lead Sponsor
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
PHASE3Active, not recruiting
11 participants
Started: Oct 24, 2022 · Completed: Jun 30, 2026
NCT05259917Lead Sponsor
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
PHASE3Completed
136 participants
Started: Feb 22, 2022 · Completed: Dec 31, 2023
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...